Ampio Pharma Financials
This page shows Ampio Pharma (AMPE) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 12 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Ampio Pharma passes 1 of 9 financial strength tests. 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).
For every $1 of reported earnings, Ampio Pharma generates $0.99 in operating cash flow (-$8.6M OCF vs -$8.6M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Key Financial Metrics
Ampio Pharma reported -$8.6M in net income in fiscal year 2023. This represents an increase of 47.2% from the prior year.
Ampio Pharma earned $-10.66 per diluted share (EPS) in fiscal year 2023. This represents an increase of 63.6% from the prior year.
Ampio Pharma held $4.1M in cash against $0 in long-term debt as of fiscal year 2023.
Ampio Pharma had 833,430 shares outstanding in fiscal year 2023. This represents an increase of 3.6% from the prior year.
Ampio Pharma invested $2.4M in research and development in fiscal year 2023. This represents a decrease of 72.6% from the prior year.
AMPE Income Statement
| Metric | Q4'23 | Q3'23 | Q3'23 | Q3'23 | Q4'22 | Q3'22 | Q3'22 | Q3'22 |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | N/A | $329K-4.4% | $344K-34.4% | $524K | N/A | $2.7M+57.6% | $1.7M-52.7% | $3.7M |
| SG&A Expenses | $1.4M+27.7% | $1.1M-11.9% | $1.2M-68.2% | $3.8M+192.3% | $1.3M-56.1% | $3.0M-8.3% | $3.2M-1.2% | $3.3M |
| Operating Income | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $8K |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | -$43.1M-3409.1% | -$1.2M+10.4% | -$1.4M+65.5% | -$4.0M-18.6% | -$3.4M+47.7% | -$6.4M-209.7% | -$2.1M+63.3% | -$5.6M |
| EPS (Diluted) | N/A | $-1.53 | $-0.09+65.4% | $-0.26 | N/A | $-10.06 | $-0.33+28.3% | $-0.46 |
AMPE Balance Sheet
| Metric | Q4'23 | Q3'23 | Q3'23 | Q3'23 | Q4'22 | Q3'22 | Q3'22 | Q3'22 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $5.7M-25.0% | $7.6M-16.4% | $9.1M-14.8% | $10.7M-21.0% | $13.6M-27.9% | $18.8M-30.8% | $27.2M-17.0% | $32.8M |
| Current Assets | $5.7M-25.0% | $7.6M-16.4% | $9.1M-14.8% | $10.7M-19.5% | $13.3M-27.2% | $18.3M-25.7% | $24.6M-17.6% | $29.9M |
| Cash & Equivalents | $4.1M-36.1% | $6.4M-8.0% | $7.0M-32.8% | $10.4M-18.2% | $12.7M-25.3% | $16.9M-26.0% | $22.9M-20.6% | $28.8M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $2.4M+4.6% | $2.3M-12.3% | $2.6M-9.4% | $2.9M+58.8% | $1.8M-63.9% | $5.0M-29.9% | $7.1M-32.4% | $10.5M |
| Current Liabilities | $2.4M+4.6% | $2.3M-9.0% | $2.5M-6.6% | $2.7M+124.2% | $1.2M-69.6% | $3.9M-22.8% | $5.1M-8.0% | $5.5M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $3.4M-37.5% | $5.4M-18.1% | $6.6M-16.7% | $7.9M-33.2% | $11.8M-14.9% | $13.8M-31.1% | $20.1M-9.7% | $22.3M |
| Retained Earnings | -$242.5M-0.9% | -$240.5M-0.5% | -$239.2M-0.6% | -$237.9M-1.7% | -$233.9M-1.0% | -$231.7M-2.8% | -$225.3M-0.9% | -$223.2M |
AMPE Cash Flow Statement
| Metric | Q4'23 | Q3'23 | Q3'23 | Q3'23 | Q4'22 | Q3'22 | Q3'22 | Q3'22 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$2.3M-316.0% | -$555K+83.7% | -$3.4M-47.7% | -$2.3M+46.4% | -$4.3M+27.7% | -$5.9M+0.1% | -$5.9M-20.3% | -$4.9M |
| Capital Expenditures | $39K+145.7% | $16K | $0-100.0% | $17K | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$2.6M+17.0% | -$3.1M-1.9% | -$3.1M-16.9% | -$2.6M+38.6% | -$4.3M+27.7% | -$5.9M+0.1% | -$5.9M-20.3% | -$4.9M |
| Investing Cash Flow | $0 | $0 | $0+100.0% | -$17K | $0 | $0 | $0 | $0 |
| Financing Cash Flow | $0 | $0 | $0 | $0 | $0 | $0 | $0+100.0% | -$111K |
| Dividends Paid | N/A | N/A | N/A | N/A | $0 | $0 | $0-100.0% | $13.0M |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
AMPE Financial Ratios
| Metric | Q4'23 | Q3'23 | Q3'23 | Q3'23 | Q4'22 | Q3'22 | Q3'22 | Q3'22 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | -281.6%-265.5pp | -16.1%-1.1pp | -15.0%+22.1pp | -37.1%-12.4pp | -24.7%+9.4pp | -34.0%-26.4pp | -7.6%+9.6pp | -17.2% |
| Current Ratio | 2.41-1.0 | 3.37-0.3 | 3.67-0.4 | 4.02-7.2 | 11.18+6.5 | 4.67-0.2 | 4.85-0.6 | 5.41 |
| Debt-to-Equity | 0.71+0.3 | 0.42+0.0 | 0.39+0.0 | 0.36+0.2 | 0.15-0.2 | 0.360.0 | 0.35-0.1 | 0.47 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Similar Companies
Frequently Asked Questions
Is Ampio Pharma profitable?
No, Ampio Pharma (AMPE) reported a net income of -$8.6M in fiscal year 2023.
What is Ampio Pharma's earnings per share (EPS)?
Ampio Pharma (AMPE) reported diluted earnings per share of $-10.66 for fiscal year 2023. This represents a 63.6% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.
What is Ampio Pharma's operating cash flow?
Ampio Pharma (AMPE) generated -$8.6M in operating cash flow during fiscal year 2023, representing cash generated from core business activities.
What are Ampio Pharma's total assets?
Ampio Pharma (AMPE) had $5.7M in total assets as of fiscal year 2023, including both current and long-term assets.
How much does Ampio Pharma spend on research and development?
Ampio Pharma (AMPE) invested $2.4M in research and development during fiscal year 2023.
How many shares does Ampio Pharma have outstanding?
Ampio Pharma (AMPE) had 833,430 shares outstanding as of fiscal year 2023.
What is Ampio Pharma's current ratio?
Ampio Pharma (AMPE) had a current ratio of 2.41 as of fiscal year 2023, which is generally considered healthy.
What is Ampio Pharma's debt-to-equity ratio?
Ampio Pharma (AMPE) had a debt-to-equity ratio of 0.71 as of fiscal year 2023, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Ampio Pharma's return on assets (ROA)?
Ampio Pharma (AMPE) had a return on assets of -150.5% for fiscal year 2023, measuring how efficiently the company uses its assets to generate profit.
What is Ampio Pharma's cash runway?
Based on fiscal year 2023 data, Ampio Pharma (AMPE) had $4.1M in cash against an annual operating cash burn of $8.6M. This gives an estimated cash runway of approximately 6 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Ampio Pharma's Piotroski F-Score?
Ampio Pharma (AMPE) has a Piotroski F-Score of 1 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Ampio Pharma's earnings high quality?
Ampio Pharma (AMPE) has an earnings quality ratio of 0.99x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.